Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Ticagrelor Does Not Improve Endothelial Dysfunction in Stable Survivors of Acute Coronary Syndrome.

Lim S, Choo EH, Kim CJ, Choi IJ, Lee KY, Hwang BH, Lee JM, Chung WS, Chang K.

J Cardiovasc Pharmacol Ther. 2019 Apr 29:1074248419841640. doi: 10.1177/1074248419841640. [Epub ahead of print]

PMID:
31035775
2.
3.

Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.

Qaderdan K, Ishak M, Heestermans AA, de Vrey E, Jukema JW, Voskuil M, de Boer MJ, van't Hof AW, Groenemeijer BE, Vos GJ, Janssen PW, Bergmeijer TO, Kelder JC, Deneer VH, ten Berg JM.

Am Heart J. 2015 Nov;170(5):981-985.e1. doi: 10.1016/j.ahj.2015.07.030. Epub 2015 Aug 4.

PMID:
26542508
5.

Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.

Pollack CV Jr, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, Schulte PJ, Spinar J, Steg PG, Storey RF, Himmelmann A, Wallentin L, Cannon CP; PLATO Investigators.

Clin Cardiol. 2017 Jun;40(6):390-398. doi: 10.1002/clc.22733. Epub 2017 Jun 9.

6.

Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.

Joshi RR, Hossain R, Morton AC, Ecob R, Judge HM, Wales C, Walker JV, Karunakaran A, Storey RF.

Platelets. 2014;25(6):416-22. doi: 10.3109/09537104.2013.836175. Epub 2013 Oct 10.

PMID:
24111601
7.

Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.

Wang H, Qi J, Li Y, Tang Y, Li C, Li J, Han Y.

Br J Clin Pharmacol. 2018 Jan;84(1):88-96. doi: 10.1111/bcp.13436. Epub 2017 Nov 3.

8.

Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.

Kim JS, Han DC, Jeong YH, Park DW, Sohn CB, Hwang KW, Lee SH, Choi JH, Chon MK, Lee SY, Hwang J, Kim IS, Lee SM, Han J, Noh M, Kim CH, Chun KJ, Park YH, Kim JH.

Thromb Haemost. 2016 Jan;115(1):213-21. doi: 10.1160/TH15-02-0180. Epub 2015 Nov 19.

PMID:
26581884
9.

Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.

Xue HJ, Shi J, Liu B, Wang DY, Dong ZX, Guo H, Kong YH, Sheng L, Shao Q, Sun DH, Zhang L, Pan YJ, Dong XW, Li JQ, Xue JY, Zhou YY, Yang HP, Li Y.

Platelets. 2016 Jul;27(5):440-5. doi: 10.3109/09537104.2015.1135890. Epub 2016 Feb 2.

PMID:
26830862
10.

Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).

Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM.

JACC Cardiovasc Interv. 2013 Jul;6(7):671-83. doi: 10.1016/j.jcin.2013.03.014.

11.

Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.

Angiolillo DJ, Franchi F, Waksman R, Sweeny JM, Raveendran G, Teng R, Zhao Y, Carlson G, Khan N, Mehran R.

J Am Coll Cardiol. 2016 Feb 16;67(6):603-613. doi: 10.1016/j.jacc.2015.11.044.

12.

Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.

Bonello L, Laine M, Camoin-Jau L, Noirot F, Guieu R, Dignat-George F, Paganelli F, Frere C.

Thromb Haemost. 2015 Oct;114(4):702-7. doi: 10.1160/TH15-02-0149. Epub 2015 Aug 27.

PMID:
26311415
13.

Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.

Nardin M, Verdoia M, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS).

Nutr Metab Cardiovasc Dis. 2016 Jul;26(7):567-574. doi: 10.1016/j.numecd.2016.03.001. Epub 2016 Mar 15.

PMID:
27134063
14.

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.

Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK; PLATO study group.

Circulation. 2014 Jan 21;129(3):293-303. doi: 10.1161/CIRCULATIONAHA.113.004420. Epub 2013 Oct 29.

PMID:
24170388
15.

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.

PMID:
19332184
16.

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.

Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park DW, Bode C, Welsh RC, Gibson CM.

Lancet. 2017 May 6;389(10081):1799-1808. doi: 10.1016/S0140-6736(17)30751-1. Epub 2017 Mar 18.

PMID:
28325638
17.

Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.

Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M; HI-TECH Investigators.

JACC Cardiovasc Interv. 2018 Aug 27;11(16):1576-1586. doi: 10.1016/j.jcin.2018.04.022. Epub 2018 May 24.

PMID:
29805112
18.

Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive 'real-world' patients.

Gosling R, Yazdani M, Parviz Y, Hall IR, Grech ED, Gunn JP, Storey RF, Iqbal J.

Platelets. 2017 Dec;28(8):767-773. doi: 10.1080/09537104.2017.1280601. Epub 2017 Mar 7.

19.

Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.

Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CP.

Clin Cardiol. 2010 Apr;33(4):206-12. doi: 10.1002/clc.20732.

20.

Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.

Ristorto J, Messas N, Marchandot B, Kibler M, Hess S, Meyer N, Schaeffer M, Tuzin N, Ohlmann P, Jesel L, Morel O.

J Atheroscler Thromb. 2018 Aug 1;25(8):674-689. doi: 10.5551/jat.40584. Epub 2018 Feb 8.

Supplemental Content

Support Center